Table 6 Total discounted direct costs, RSV-related hospitalizations, and QALYs of palivizumab vs. placebo in infants with CHD, Colombia, 2022
Outcome | No palivizumab | Palivizumab |
|---|---|---|
Total discounted direct costs | $ 3,921,289 | $ 2,811,495 |
RSV-related hospitalizations | 194 | 106 |
∆ Costs (palivizumab– no palivizumab) | - $ 1,109,794 | |
∆ QALYs (palivizumab– no palivizumab) | 40 | |